Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Expected survival of at least 3 months; [+6]
Pregnant or breastfeeding women; [+9]
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
Willing to participate in this clinical study and sign an informed consent form; [+14]
Pregnant or lactating women; [+19]
This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Willing to participate in this clinical study and sign an informed consent form; [+8]
Pregnant or lactating women; [+12]
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
Aged 18-65 years; both genders eligible. [+11]
History of solid organ transplantation. [+7]
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.
Aged 18-65 years ; both genders eligible. [+4]
History of solid organ transplantation. [+7]
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.
Age range from 18 to 65 years old (including threshold), regardless of gender; [+15]
Have a serious history of Drug allergy or allergic constitution; [+15]
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)
Subject (or their legally authorized representative or guardian) will sign and d... [+7]
Known contraindications, intolerance, or hypersensitivity to hematopoietic stem... [+23]
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Provision of written informed consent for this study by subjects, or as applicab... [+1]
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Provision of written informed consent for this study by subjects, or as applicab... [+1]